Top 10 Dividend Aristocrats for 2026: Which Ones Are Still Worth Buying?

Last Updated: March 4, 2026

Dividend Aristocrats are the royalty of the stock market. These are S&P 500 companies that have increased their dividend every single year for at least 25 consecutive years — through recessions, pandemics, wars, financial crises, and every other curveball the economy has thrown.

That kind of track record doesn't happen by accident. It requires durable competitive advantages, disciplined management, and business models that generate consistent cash flow in any environment.

But here's the thing: not all Aristocrats are created equal. Some are trading at bargain prices with room to grow. Others are overvalued, overleveraged, or facing structural challenges that put their dividend streaks at risk.

Let's break down the 10 most popular Dividend Aristocrats and answer the question that actually matters: are they still worth buying in 2026?

What Makes a Dividend Aristocrat?

To earn the title, a company must:

1. Be a member of the S&P 500
2. Have increased its dividend for 25+ consecutive years
3. Meet minimum size and liquidity requirements

As of 2026, there are roughly 67 Dividend Aristocrats. The list gets updated annually — companies that freeze or cut their dividends get removed, and new qualifiers get added.

Now let's look at the top 10.

1. Coca-Cola (KO)

Consecutive dividend increases: 62 years Current dividend yield: ~3.0% Payout ratio: ~72% 5-year dividend growth rate: ~3.5%

The case for KO: It's the ultimate "sleep well at night" stock. Coca-Cola owns some of the most recognized brands on Earth, operates in 200+ countries, and has pricing power that few companies can match. The shift toward zero-sugar products and emerging market growth provide a solid runway.

The case against: Growth is modest. At a P/E around 24, you're paying a premium for stability. If you're under 40 and want capital appreciation, there are better options.

Verdict: BUY for income portfolios. KO isn't going to make you rich, but it's unlikely to hurt you. The yield is solid, the dividend is as safe as they come, and the brand portfolio provides a genuine moat. Just don't expect double-digit returns.

Use our Dividend Calculator to model what KO's dividend could grow to over the next 10–20 years.

2. Johnson & Johnson (JNJ)

Consecutive dividend increases: 62 years Current dividend yield: ~3.3% Payout ratio: ~45% 5-year dividend growth rate: ~5.5%

The case for JNJ: Post-Kenvue spinoff, JNJ is a focused pharmaceutical and medical device powerhouse. The payout ratio is conservatively low (plenty of room to grow), and the pipeline of drugs in development is one of the strongest in the industry.

The case against: Talc litigation remains a lingering risk, though the company has been working to resolve it. Patent cliffs on key drugs (like Stelara) could pressure near-term earnings.

Verdict: STRONG BUY. JNJ might be the single best Dividend Aristocrat to buy right now. The yield is above average, the payout ratio gives a massive cushion, and the stock has been trading below its historical valuation multiples. This is exactly the kind of stock Graham would approve of.

3. Procter & Gamble (PG)

Consecutive dividend increases: 68 years Current dividend yield: ~2.4% Payout ratio: ~62% 5-year dividend growth rate: ~6%

The case for PG: P&G owns Tide, Pampers, Gillette, Crest, Charmin, and dozens of other brands that people buy regardless of economic conditions. Pricing power is strong, and the company has consistently grown earnings through cost optimization and premiumization.

The case against: The yield is on the lower end for income investors. Valuation is stretched at 25x+ earnings. Consumer staples face increasing competition from private-label brands.

Verdict: HOLD. PG is a great company at a full price. If you already own it, keep it. But if you're starting a new position, waiting for a pullback to the $150 range would give you a better entry point and a higher effective yield.

4. 3M Company (MMM)

Consecutive dividend increases: 65+ years Current dividend yield: ~2.1% Payout ratio: ~40% 5-year dividend growth rate: ~1%

The case for MMM: 3M has been through the wringer — PFAS litigation, earplug lawsuits, a healthcare spinoff (Solventum), and years of underperformance. But the stock has recovered meaningfully from its lows, the legal overhang is largely resolved, and the remaining business is leaner and more focused.

The case against: Dividend growth has been minimal. The company is in restructuring mode, and it's unclear whether the new, slimmer 3M can reignite growth. The yield has compressed significantly from its highs.

Verdict: SPECULATIVE BUY. 3M is more of a turnaround bet than a classic income play at this point. The dividend streak is intact, but barely. If you believe in the restructuring story, there could be upside. But for reliable income, look elsewhere.

5. PepsiCo (PEP)

Consecutive dividend increases: 52 years Current dividend yield: ~3.6% Payout ratio: ~68% 5-year dividend growth rate: ~7%

The case for PEP: PepsiCo isn't just soda — it's Frito-Lay, Quaker Oats, Gatorade, and a massive snack empire. The snack business provides higher margins and growth than beverages, making PEP arguably more diversified than KO. Recent share price weakness has pushed the yield to attractive levels.

The case against: Volume growth has slowed as consumers push back against price increases. International currency headwinds remain a concern.

Verdict: STRONG BUY. PEP at a 3.6% yield with 7% dividend growth is a compelling combination. The stock has underperformed recently, creating an entry point that income investors should seriously consider. Diversified revenue streams and strong free cash flow make the dividend very safe.

6. AbbVie (ABBV)

Consecutive dividend increases: 52 years (counting pre-Abbott split history) Current dividend yield: ~3.5% Payout ratio: ~55% 5-year dividend growth rate: ~8%

The case for ABBV: AbbVie has navigated the Humira patent cliff better than anyone expected. Skyrizi and Rinvoq are growing rapidly and are on track to more than replace lost Humira revenue. The company has one of the best growth + income profiles in the market.

The case against: Pharma stocks always carry pipeline risk. If Skyrizi or Rinvoq face unexpected competition or safety issues, the thesis breaks.

Verdict: BUY. AbbVie has successfully managed one of the biggest patent cliffs in pharmaceutical history. The dividend yield is excellent, growth is strong, and the pipeline is deep. One of the best Aristocrats for total return.

7. Realty Income (O)

Consecutive dividend increases: 30 years Current dividend yield: ~5.6% Payout ratio: ~75% (of AFFO) 5-year dividend growth rate: ~4%

The case for O: Realty Income is the gold standard of REITs. It pays dividends monthly (not quarterly), owns 15,000+ commercial properties leased to high-quality tenants (Walmart, Dollar General, FedEx), and has the longest dividend increase streak of any REIT.

The case against: Higher interest rates have pressured all REITs. Realty Income's cost of capital is higher than it was in the low-rate era, potentially slowing acquisitions and growth.

Verdict: BUY for income. At a 5.6% yield, Realty Income is paying you well to wait for rate normalization. The portfolio is diversified, the tenants are strong, and the monthly dividend is a nice psychological bonus. Just understand this is an income play, not a growth play.

8. McDonald's (MCD)

Consecutive dividend increases: 48 years Current dividend yield: ~2.4% Payout ratio: ~57% 5-year dividend growth rate: ~8%

The case for MCD: McDonald's is a real estate and franchise machine disguised as a burger chain. The asset-light model generates enormous free cash flow, and the company has consistently returned capital to shareholders. Digital ordering, delivery partnerships, and menu innovation keep the brand relevant.

The case against: Valuation is premium (26x+ earnings). Consumer spending pressures could slow same-store sales growth. The yield is relatively low for income-focused investors.

Verdict: HOLD. MCD is a phenomenal business, but you're paying for that quality. Like PG, it's a better buy on dips. If you already own it, the dividend growth trajectory is excellent. If you're starting fresh, be patient.

9. Target (TGT)

Consecutive dividend increases: 56 years Current dividend yield: ~3.4% Payout ratio: ~47% 5-year dividend growth rate: ~12%

The case for TGT: Target has been one of the best dividend growth stories of the past decade, more than tripling its dividend. The low payout ratio provides a massive safety buffer, and the company's omnichannel strategy (same-day delivery, in-store pickup) positions it well against Amazon.

The case against: Retail is inherently volatile. Target had a rough 2022–2023 with inventory and margin issues, though it has largely recovered. Consumer discretionary spending is vulnerable in a slowdown.

Verdict: BUY. The 12% dividend growth rate is exceptional for an Aristocrat. Combined with a 3.4% current yield and sub-50% payout ratio, Target offers both income now and rapid dividend growth ahead. The stock's recovery from its lows makes this a well-timed entry.

10. Automatic Data Processing (ADP)

Consecutive dividend increases: 49 years Current dividend yield: ~2.0% Payout ratio: ~58% 5-year dividend growth rate: ~12%

The case for ADP: ADP processes payroll for 1 in 6 US workers. That's an incredibly sticky business — switching payroll providers is painful, so clients rarely leave. Revenue is recurring, margins are expanding, and the company benefits from rising interest rates (it earns float on client funds).

The case against: The stock trades at a premium (~28x earnings). Employment downturns directly impact revenue. The yield is relatively low.

Verdict: BUY on dips. ADP is a best-in-class business with a near-monopolistic position in payroll processing. The 12% dividend growth rate means today's 2% yield becomes much more significant over time. But at current valuations, patience for a better entry would serve you well.

Building a Dividend Aristocrat Portfolio

Here's a sample portfolio allocation using our top picks:

| Stock | Allocation | Yield | Role | |---|---|---|---| | JNJ | 15% | 3.3% | Healthcare anchor | | PEP | 15% | 3.6% | Consumer staples | | ABBV | 15% | 3.5% | Pharma growth + income | | O | 15% | 5.6% | High yield, monthly income | | TGT | 10% | 3.4% | Dividend growth | | KO | 10% | 3.0% | Stability | | ADP | 10% | 2.0% | Business services | | MMM | 5% | 2.1% | Turnaround upside | | MCD | 5% | 2.4% | Franchise quality |

Blended yield: ~3.5% with strong dividend growth potential.

Use our Dividend Calculator to project how this portfolio's income would grow over 10, 20, or 30 years with reinvested dividends.

How to Evaluate Dividend Aristocrats

Before buying any Aristocrat, check these five metrics:

1. Payout ratio — Under 60% is ideal. Over 80% is a warning sign.
2. Dividend growth rate — Higher is better, but it should be sustainable.
3. Free cash flow coverage — The dividend should be well-covered by free cash flow, not just earnings.
4. Debt levels — Heavy debt can force dividend cuts in downturns.
5. Valuation — Even great companies can be bad investments at the wrong price. Use our P/E Analyzer to compare current valuations to historical averages.

The Bottom Line

Dividend Aristocrats have earned their reputation. A 25+ year track record of dividend increases through every kind of crisis is about as close to a guarantee as the stock market offers.

But reputation alone isn't enough. The best Aristocrats in 2026 are the ones trading at reasonable valuations with strong dividend growth potential and sustainable payout ratios.

Our top picks: JNJ, PEP, ABBV, Realty Income, and Target — each offers a compelling blend of current yield, dividend growth, and value.

The most overvalued: PG, MCD, and ADP — wonderful companies that are priced for perfection. Wait for a pullback.

Build your watchlist, do the math, and let compound dividends do the heavy lifting.

---

Model your dividend income with our Dividend Calculator and compare Aristocrats side by side with our Stock Comparison tool.